Lin Wang1, Carlos D Rosé2, Kevin P Foley1, Jordi Anton3, Brigitte Bader-Meunier4, Philippe Brissaud5, Gaelle Chédeville6, Rolando Cimaz7, Jorge Fernández-Martín8, Catherine Guly9, Eric Hachulla10, Miroslav Harjacek11, Friederike Mackensen12, Rosa Merino13, Consuelo Modesto14, Antonio Naranjo Hernández15, Christine Pajot16, Athimalaipet V Ramanan17, Akaluck Thatayatikom18, Caroline Thomée19, Sebastiaan Vastert20, Bart J Votta1, John Bertin1, Carine H Wouters21. 1. Pattern Recognition Receptor Discovery Performance Unit, Immuno-Inflammation Therapeutic Area, GlaxoSmithKline, Collegeville, PA, USA. 2. Pediatrics, Nemours/Alfred I. duPont Hospital for Children, Wilmington, DE, USA. 3. Pediatric Rheumatology, Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain. 4. 5 Service d'Immunologie- Hematologie et Rhumatologie Pediatrique, Hôpital Necker-Enfants Malades, Institut Imagine, Paris, France. 5. Médecine Interne Rhumatologie, Hôpital Bichat-Claude Bernard, Paris, France. 6. Division of Rheumatology, The Montreal Children's Hospital, Montreal, Quebec, Canada. 7. AOU Meyer, Meyer Children's Hospital, Florence, Italy. 8. Internal Medicine, Hospital do Meixoeiro-Chuvi, Vigo, Pontevedra, Spain. 9. Retina Unit, Bristol Eye Hospital, Bristol, UK. 10. Service de Médecine Interne, Hôpital Claude Huriez, Lille, France. 11. Rheumatology, Children's Hospital Srebrnjak, Zagreb, Croatia. 12. Interdisciplinary Uveitis Center, Universitat Klinikum Heidelberg, Heidelberg, Germany. 13. Unidad de Reumatologia Pediatrica, Hospital La Paz, Madrid, Barcelona, Spain. 14. Pediatric Rheumatology, Hospital Universitario Vall d'Hebron, Barcelona, Spain. 15. Servicio de Rheumatologia, Hospital de Gran Canarias Dr Negrin, Las Palmas, Spain. 16. Service Urgences & Service Médecine Interne-Rhumatologie, Hôpital des Enfants, Toulouse, France. 17. Department of Paediatric Rheumatology, University Hospitals Bristol NHS Foundation Trust and University of Bristol, Bristol, UK. 18. Division of Allergy/Immunology/Rheumatology, Department of Pediatrics, University of Florida, Gainesville, FL, USA. 19. Service de Pédiatrie, Clinique Pédiatrique CHL, Luxembourg, Luxembourg. 20. Division of Pediatrics, Department of Pediatric Rheumatology and Immunology, UMC Utrecht, Utrecht, The Netherlands. 21. KU Leuven, Department of Microbiology and Immunology, Pediatric Immunology, University Hospitals Leuven, Pediatric Rheumatology, Leuven, Belgium.
Abstract
OBJECTIVE: To identify biomarkers of articular and ocular disease activity in patients with Blau syndrome (BS). METHODS: Multiplex plasma protein arrays were performed in five BS patients and eight normal healthy volunteers (NHVs). Plasma S100A12 and S100A8/9 were subsequently measured by ELISA at baseline and 1-year follow-up in all patients from a prospective multicentre cohort study. CRP was measured using Meso Scale Discovery immunoassay. Active joint counts, standardization uveitis nomenclature for anterior uveitis cells and vitreous haze by Nussenblatt scale were the clinical parameters. RESULTS: Multiplex Luminex arrays identified S100A12 as the most significantly elevated protein in five selected BS vs eight NHVs and this was confirmed by ELISA on additional samples from the same five BS patients. In the patient cohort, S100A12 (n = 39) and S100A8/9 (n = 33) were significantly higher compared with NHVs (n = 44 for S100A12, n = 40 for S100A8/9) (P = 0.0000004 and P = 0.0003, respectively). Positive correlations between active joint counts and S100 levels were significant for S100A12 (P = 0.0008) and S100A8/9 (P = 0.015). CRP levels did not correlate with active joint count. Subgroup analysis showed significant association of S100 proteins with active arthritis (S100A12 P = 0.01, S100A8/9 P = 0.008). Active uveitis was not associated with increased S100 levels. CONCLUSION: S100 proteins are biomarkers of articular disease activity in BS and potential outcome measures in future clinical trials. As secreted neutrophil and macrophage products, S100 proteins may reflect the burden of granulomatous tissue in BS.
OBJECTIVE: To identify biomarkers of articular and ocular disease activity in patients with Blau syndrome (BS). METHODS: Multiplex plasma protein arrays were performed in five BSpatients and eight normal healthy volunteers (NHVs). Plasma S100A12 and S100A8/9 were subsequently measured by ELISA at baseline and 1-year follow-up in all patients from a prospective multicentre cohort study. CRP was measured using Meso Scale Discovery immunoassay. Active joint counts, standardization uveitis nomenclature for anterior uveitis cells and vitreous haze by Nussenblatt scale were the clinical parameters. RESULTS: Multiplex Luminex arrays identified S100A12 as the most significantly elevated protein in five selected BS vs eight NHVs and this was confirmed by ELISA on additional samples from the same five BSpatients. In the patient cohort, S100A12 (n = 39) and S100A8/9 (n = 33) were significantly higher compared with NHVs (n = 44 for S100A12, n = 40 for S100A8/9) (P = 0.0000004 and P = 0.0003, respectively). Positive correlations between active joint counts and S100 levels were significant for S100A12 (P = 0.0008) and S100A8/9 (P = 0.015). CRP levels did not correlate with active joint count. Subgroup analysis showed significant association of S100 proteins with active arthritis (S100A12 P = 0.01, S100A8/9 P = 0.008). Active uveitis was not associated with increased S100 levels. CONCLUSION: S100 proteins are biomarkers of articular disease activity in BS and potential outcome measures in future clinical trials. As secreted neutrophil and macrophage products, S100 proteins may reflect the burden of granulomatous tissue in BS.
Authors: Jonas J W Kuiper; Fleurieke H Verhagen; Sanne Hiddingh; Roos A W Wennink; Anna M Hansen; Kerry A Casey; Imo E Hoefer; Saskia Haitjema; Julia Drylewicz; Mehmet Yakin; H Nida Sen; Timothy R D J Radstake; Joke H de Boer Journal: Ophthalmol Sci Date: 2022-05-31